Introduction {#s1}
============

Osteoporosis is a complex disease with reduced bone mineral density (BMD) and increased fracture risk ([@B36]). Until now, large-scale genome-wide association studies (GWAS) based on single genetic variant have reported some novel osteoporosis susceptibility variants ([@B4]; [@B30]; [@B36]). These osteoporosis genetic variants include rs2062375, rs13182402, rs7605378, rs12775980, rs494453, and rs784288 ([@B4]; [@B8]; [@B16]; [@B9]; [@B35]). Meanwhile, some BMD related genetic variants were also identified ([@B12]; [@B14]; [@B34]). In 2017, Kemp et al. performed a GWAS of heel BMD using 142,487 individuals from the UK Biobank ([@B12]). They identified 307 conditionally independent genetic variants with genome-wide significance at 203 loci including 153 novel loci ([@B12]). In 2018, Kim et al. conducted a GWAS of heel BMD using the data from UK Biobank, and identified 1,362 independent genetic variants with genome-wide significance around 899 loci including 613 novel loci ([@B14]). In 2019, Styrkarsdottir et al. performed a GWAS of hip and lumbar spine BMD, and identified 13 independent genetic variants at 12 loci ([@B34]).

However, these risk variants only explain a small proportion of osteoporosis genetic risk, and most genetic risk is largely unknown ([@B36]). Considering the limitations of GWAS on single genetic variant level, some improved method named pathway analysis of GWAS dataset or gene set analysis has been proposed and widely used in multiple human complex diseases ([@B1]; [@B7]; [@B19]; [@B6]; [@B20]; [@B21]; [@B28]; [@B11]; [@B22]).

Interestingly, the pathway analysis method has also been used in investigation of osteoporosis mechanisms and reported some novel pathways ([@B40]; [@B17]; [@B36]). In addition to these risk pathways above, it remains unclear whether there are other risk pathways involved in BMD. Hence, we conducted a pathway analysis of hip BMD GWAS with 301,019 SNPs in 5,858 Europeans using a published gene-based analysis method (SET SCREEN TEST) ([@B24]) and a pathway-based analysis method (WebGestalt) ([@B39]).

Materials and Methods {#s2}
=====================

The BMD GWAS Dataset {#s2_1}
--------------------

This study included 5,861 Icelandic persons, and 5,858 of 5,861 persons had measurements of hip bone mineral density ([@B32]). For each DNA sample, the Infinium HumanHap300 or the HumanCNV370 SNP chip (Illumina) was used to genotype a total of 317,503 genetic variants ([@B32]). After quality control, the GWAS dataset finally included 301,019 common genetic variants ([@B32]). In order to evaluate the association between each genetic variant and BMD, a linear regression method was utilized ([@B32]). Here, we used the summary results from this BMD GWAS ([@B32]). More detailed results are described in the original study ([@B32]).

Gene-Based Testing for BMD GWAS by a Meta-Analysis Method {#s2_2}
---------------------------------------------------------

We selected a set screen test method implemented in PLINK to perform a gene-based test of the whole GWAS dataset ([@B24]). The method could combine all *P* values from all the genetic variants in each corresponding gene by an approximate Fisher's test and could also adjust for the linkage disequilibrium (LD) ([@B24]).

For all genetic variants in a specific gene, if all these genetic variants are independent, the Fisher's statistic could be calculated by
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where *N* is the number of selected genetic variants in a specific gene and *p~i~* (*i* = 1, ..., N) is the significance level about the association each genetic variant with BMD, *x* ~0~ ^2^ follows a chi-square distribution with the freedom degrees = 2*N* ([@B24]).

If the selected genetic variants are not independent,
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where *x* ^2^ follows the central chi-square distribution with 8*N* ^2^/*σ* ^2^ as degrees of freedom ([@B24]). Here, the LD information is from the HapMap CEU population.

Pathway-Based Testing for BMD GWAS Dataset {#s2_3}
------------------------------------------

Here, we conducted a KEGG pathway analysis of the BMD risk genes using WebGestalt ([@B39]). The enrichment analysis was performed using the hypergeometric test ([@B39]). Here, we selected the entire entrez gene set as the reference gene assuming including *N* genes. We first assume that we have identified *S* BMD risk genes using the gene-base test. For a given pathway, we further assume that this pathway includes *m* genes and *K* BMD risk genes. The significant levels observing *K* BMD risk genes in a specific pathway is
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Meanwhile, we limited the pathway analysis using the KEGG pathways with at least 20 and at most 300 genes. A false discovery rate (FDR) method was used to adjust the original significance levels. Here, we define a pathway with adjusted *P* \< 0.01 to be statistically significant.

Results {#s3}
=======

Gene-Based Test for BMD GWAS Dataset {#s3_1}
------------------------------------

Using the gene-based test, several BMD susceptibility genes reported by previous GWAS were among the top 10 significant signals, which included CKAP5 (the most significant signal with *P* = 4.03E-07) ([@B33]), LRP4 (the most significant signal with *P* = 6.72E-05) ([@B33]), and C6orf97 (the 6^th^ significant signal with *P* = 1.04E-04) ([@B33]). Meanwhile, we identified other new BMD susceptibility genes, such as F2 (the second significant signal with *P* = 1.58E-05), LALBA (the 4^th^ significant signal with *P* = 6.86E-05), and CPN2 (the 5^th^ significant signal with *P* = 7.21E-05). Detailed information about the 5% significant genes is described in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}.

Pathway-Based Test for BMD GWAS Dataset {#s3_2}
---------------------------------------

We used the top 5% significant signals (14,008\*5% = 700 genes with *P* \< 0.04239) from the gene-based test for following pathway analysis. We identified 27 significant KEGG pathways (adjusted *P* \< 0.01) ([**Table 1**](#T1){ref-type="table"}). Based on the function classifications, these pathways are mainly related to immunity, cellular processes, environment, infection, cardiovascular diseases, metabolism, and circulation. The top three significant signals are related with immune system including T cell receptor signaling pathway (hsa04660), complement and coagulation cascades (hsa04610), and intestinal immune network for IgA production (hsa04672) as described in [**Table 1**](#T1){ref-type="table"}. The detailed information is provided in [**Supplementary Table 2**](#SM1){ref-type="supplementary-material"}.

###### 

Significant KEGG pathways with *P* \< 0.01 by pathway-based analysis of BMD GWAS.

  Classification                         Pathway ID   Pathway Name                                                   C     O    E      R      rawP       adjP
  -------------------------------------- ------------ -------------------------------------------------------------- ----- ---- ------ ------ ---------- ----------
  Immune system                          hsa04660     T cell receptor signaling pathway                              108   9    1.61   5.58   3.68E-05   8.00E-04
  Immune system                          hsa04610     Complement and coagulation cascades                            69    7    1.03   6.79   7.76E-05   8.00E-04
  Immune system                          hsa04672     Intestinal immune network for IgA production                   48    6    0.72   8.37   7.80E-05   8.00E-04
  Cardiovascular diseases                hsa05414     Dilated cardiomyopathy                                         90    8    1.34   5.95   6.26E-05   8.00E-04
  Infectious diseases: parasitic         hsa05146     Amoebiasis                                                     106   8    1.58   5.05   2.00E-04   1.30E-03
  Metabolism                             hsa00564     Glycerophospholipid metabolism                                 80    7    1.19   5.86   2.00E-04   1.30E-03
  Environmental information processing   hsa04310     Wnt signaling pathway                                          150   9    2.24   4.02   4.00E-04   2.30E-03
  Infectious diseases: bacterial         hsa05120     Epithelial cell signaling in *Helicobacter pylori* infection   68    6    1.02   5.91   5.00E-04   2.60E-03
  Circulatory system                     hsa04972     Pancreatic secretion                                           101   7    1.51   4.64   8.00E-04   3.50E-03
  Infectious diseases: parasitic         hsa05145     Toxoplasmosis                                                  132   8    1.97   4.06   9.00E-04   3.50E-03
  Cellular processes                     hsa04144     Endocytosis                                                    201   10   3      3.33   1.00E-03   3.50E-03
  Endocrine system                       hsa04916     Melanogenesis                                                  101   7    1.51   4.64   8.00E-04   3.50E-03
  Infectious diseases: viral             hsa05160     Hepatitis C                                                    134   8    2      4      1.00E-03   3.50E-03
  Cellular processes                     hsa04146     Peroxisome                                                     79    6    1.18   5.09   1.20E-03   3.90E-03
  Cardiovascular diseases                hsa05410     Hypertrophic cardiomyopathy (HCM)                              83    6    1.24   4.84   1.50E-03   4.30E-03
  Cellular processes                     hsa04114     Oocyte meiosis                                                 112   7    1.67   4.19   1.50E-03   4.30E-03
  Immune system                          hsa04621     NOD-like receptor signaling pathway                            58    5    0.87   5.77   1.70E-03   4.40E-03
  Environmental information processing   hsa04512     ECM-receptor interaction                                       85    6    1.27   4.73   1.70E-03   4.40E-03
  Environmental information processing   hsa04630     Jak-STAT signaling pathway                                     155   8    2.31   3.46   2.40E-03   5.90E-03
  Environmental information processing   hsa04080     Neuroactive ligand-receptor interaction                        272   11   4.06   2.71   2.80E-03   6.60E-03
  Genetic information processing         hsa03040     Spliceosome                                                    127   7    1.9    3.69   3.10E-03   6.70E-03
  Metabolism                             hsa00230     Purine metabolism                                              162   8    2.42   3.31   3.10E-03   6.70E-03
  Cellular processes                     hsa04510     Focal adhesion                                                 200   9    2.99   3.01   3.30E-03   6.90E-03
  Environmental information processing   hsa04514     Cell adhesion molecules (CAMs)                                 133   7    1.99   3.52   4.00E-03   7.80E-03
  Circulatory system                     hsa04976     Bile secretion                                                 71    5    1.06   4.72   4.20E-03   7.80E-03
  Immune system                          hsa04622     RIG-I-like receptor signaling pathway                          71    5    1.06   4.72   4.20E-03   7.80E-03
  Cellular processes                     hsa04810     Regulation of actin cytoskeleton                               213   9    3.18   2.83   5.00E-03   9.00E-03

C, number of reference genes in the category; O, number of genes in the gene set and also in the category; E, expected number in the category; R, ratio of enrichment; rawP, p value from hypergeometric test; adjP, p value adjusted by the multiple test adjustment.

Verification by PubMed and Google Scholar Literature Search {#s3_3}
-----------------------------------------------------------

We further verified these findings from pathway analysis using publicly available literatures in PubMed and Google Scholar databases. Interestingly, growing evidence supports the involvement of dilated cardiomyopathy and hypertrophic cardiomyopathy, T cell receptor signaling pathway, wnt signaling pathway, and regulation of actin cytoskeleton in MBD. More detailed information is described in [**Table 2**](#T2){ref-type="table"}.

###### 

Literature evidences supporting that genes in measles pathway are associated with bone mineral density or osteoporosis.

  Pathway                                                  Supporting evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Ref
  -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Dilated cardiomyopathy and hypertrophic cardiomyopathy   Evidence has also shown that both Dilated cardiomyopathy and Hypertrophic cardiomyopathy could result in heart failure ([@B26]; [@B18]). Cross-sectional studies have shown that more than 50% of patients with congestive heart failure (CHF) have decreased bone mineral density (BMD) ([@B3]). Heart failure (HF) is associated with several factors that contribute to both reduced bone mineral density and increased risk of osteoporosis-related fractures ([@B23]).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ([@B26]; [@B18]; [@B3]; [@B23])
  T cell receptor signaling pathway                        T lymphocytes and their products act as key regulators of osteoclast formation, life span, and activity. This review presents this understanding of the process of T lymphocytes and their products mediating osteoporosis and explores some of the most recent findings and hypotheses to explain their action in bone ([@B41]). Our results show that activated T cells can regulate systemic and local bone loss through OPGL. In summary, activated T cells produce OPGL and can directly trigger osteoclastogenesis *in vitro*; activated T cells from ctla4-/- mice have a destructive effect on bone mineral density *in vivo* that can be reversed through inhibition of OPGL; and inhibition of OPGL through OPG can completely prevent bone and cartilage loss in a T-cell-dependent arthritis model ([@B15]).                                                                                                                                                     ([@B15]; [@B41])
  Wnt signaling pathway                                    Wnt signaling pathway regulates bone mineral density (BMD) through the lipoprotein receptor-related protein (LRP) 5, a receptor of this signaling. Genetic variations at the *LRP5* gene locus are associated with osteoporosis. These data suggest that genetic variations in Wnt signaling genes may affect the pathogenesis of osteoporosis ([@B27]). Wnt signaling has emerged to play major roles in almost all aspects of skeletal development and homeostasis. Wnt signaling has become a focal point of intensive studies in skeletal development and disease. Promising effective therapeutic agents for bone diseases are being developed by targeting the Wnt signaling pathway ([@B29]). We identified 56 loci (32 new) associated with BMD at genome-wide significance (*P* \< 5 × 10^−8^). Several of these factors cluster within the RANK-RANKL-OPG, mesenchymal stem cell differentiation, endochondral ossification, and Wnt signaling pathways ([@B2]).   ([@B27]; [@B2]; [@B29])
  Regulation of actin cytoskeleton                         The focal adhesion, the actin cytoskeleton and cell-cycle are connected pathways ([@B42]). Data from 211 studies that investigated the association between BMD and gene variants involved in these pathways were catalogued in a web-based information system and analyzed ([@B42]). The results showed that genes in these three pathways are implicated in the pathogenesis of low BMD ([@B42]). Genome-wide linkage studies have highlighted the chromosomal region 3p14-p22 as a quantitative trait locus for BMD ([@B25]). The *FLNB* gene, which is thought to have a role in cytoskeletal actin dynamics, is located within this chromosomal region and presents as a strong candidate for BMD regulation ([@B25]). Mullin et al. identified significant associations between SNPs in the *FLNB* gene and BMD in Caucasian women ([@B25]).                                                                                                                            ([@B42]; [@B25])

Discussion {#s4}
==========

Until now, pathway analysis of BMD GWAS datasets has identified several risk pathways. However, most genetic variants, risk genes, and genetic pathways influencing osteoporosis are unknown. In order to identify novel BMD risk pathways, we conducted a pathway analysis of hip BMD GWAS with 301,019 genetic variants in 5,858 Europeans using the meta-analysis method (SET SCREEN TEST) in PLINK ([@B24]) and a pathway-based analysis method (WebGestalt) ([@B39]).

On the gene level, we confirmed previous identified BMD susceptibility genes such as *CKAP5* ([@B33]), *LRP4* ([@B33]), and *C6orf97* ([@B33]). All these genes are ranked top 10 significant signals. We also identified some new BMD susceptibility genes, which were significantly associated with BMD with *P* \< 0.0001. Take the second significant signal *F2* for example, *F2* could encode coagulation factor II, thrombin ([@B31]). Pro-thrombin is cut to generate thrombin in the coagulation cascade, and further reduce the blood loss ([@B31]). It is common that procoagulant state could active thrombin in bone fracture sites ([@B31]). Take *CPN2* for example, two genetic variants rs11711157 and rs3732477 near *CPN2* have been reported to be associated with BMD in Koreans ([@B13]). These findings suggest that the meta-analysis method (SET SCREEN TEST) is effective to identify BMD susceptibility genes.

On the pathway level, we identified 27 significant KEGG pathways. Three immune pathways including T cell receptor signaling pathway (hsa04660), complement and coagulation cascades (hsa04610), and intestinal immune network for IgA production (hsa04672) are ranked the top three significant signals. In addition, we also identified other kinks of pathways associated with cellular processes, environmental information processing, infectious diseases, cardiovascular diseases, metabolism, and circulatory system, are also identified. In order to further evaluate the potential roles of these newly identified risk pathways, we conducted a comprehensive literature review. Interestingly, growing evidence from the PubMed and Google Scholar databases further supports the involvement of dilated cardiomyopathy, hypertrophic cardiomyopathy, T cell receptor signaling pathway, wnt signaling pathway, and regulation of actin cytoskeleton in MBD, as provided in [**Table 2**](#T2){ref-type="table"}.

In a recent study, Guo et al. conducted a pathway and network analysis of genes related to osteoporosis ([@B5]). They first retrieved 94 osteoporosis genes from PubMed ([@B5]). They further conducted an enrichment analysis, and found that these osteoporosis genes were significantly enriched in biological processes related to bone metabolism and the immune system ([@B5]). Take wnt signaling pathway for example, we identified wnt signaling to be the 7^th^ significant pathway, as provided in [**Table 1**](#T1){ref-type="table"}. Interestingly, Guo et al. identified wnt signaling to be the second significant pathway with *P* = 3.71 × 10^−13^ ([@B5]). Hence, our findings are consistent with recent findings.

Our study has a main difference with previous studies. In recent years, most studies focus on the single genetic variant associated with BMD, osteoporosis, or fracture ([@B12]; [@B14]; [@B34]). However, these genetic variants only explain a small proportion of osteoporosis genetic risk ([@B36]). Hence, pathway analysis of GWAS dataset may overcome the limitations of single genetic variant. However, our current study still has some limitations. First, the sample size is relatively small and lacks validation cohort to test the robustness of these findings. In future study, we will further select other BMD GWAS datasets with large-scale sample size to demonstrate our findings. Second, we only selected one gene based method and one pathway based method. In future, we will verify our findings using other gene and pathway based methods. Third, we selected the top 5% significant signals from the gene-based test for following pathway analysis, as did in recent studies ([@B38]; [@B10]; [@B37]). Using this strategy, we selected 700 BMD risk genes with *P* \< 0.04239. In fact, there are a total of 813 BMD risk genes with *P* \< 0.05. Hence, our current pathway analysis findings are consistent with those using 813 BMD risk genes (data now shown). However, selection of different thresholds may have different findings, as described in recent studies ([@B38]; [@B10]; [@B37]).

In summary, two studies reported regulation-of-autophagy and other eight significant pathways ([@B40]; [@B17]). Our findings provide complementary information to these nine risk pathways. Meanwhile, future studies using large-scale sample sizes should further verify our findings.
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